Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Assets Average (2019 - 2025)

BridgeBio Pharma's Assets Average history spans 7 years, with the latest figure at $967.1 million for Q4 2025.

  • For Q4 2025, Assets Average rose 22.09% year-over-year to $967.1 million; the TTM value through Dec 2025 reached $967.1 million, up 22.09%, while the annual FY2025 figure was $927.7 million, 26.58% up from the prior year.
  • Assets Average for Q4 2025 was $967.1 million at BridgeBio Pharma, down from $1.0 billion in the prior quarter.
  • Across five years, Assets Average topped out at $1.1 billion in Q2 2021 and bottomed at $564.7 million in Q2 2023.
  • The 5-year median for Assets Average is $829.8 million (2022), against an average of $816.7 million.
  • The largest annual shift saw Assets Average plummeted 32.59% in 2023 before it skyrocketed 45.55% in 2024.
  • A 5-year view of Assets Average shows it stood at $897.2 million in 2021, then fell by 24.66% to $675.9 million in 2022, then dropped by 11.13% to $600.7 million in 2023, then soared by 31.87% to $792.2 million in 2024, then grew by 22.09% to $967.1 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Assets Average are $967.1 million (Q4 2025), $1.0 billion (Q3 2025), and $980.9 million (Q2 2025).